<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="552">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520998</url>
  </required_header>
  <id_info>
    <org_study_id>ALK6019-201</org_study_id>
    <nct_id>NCT03520998</nct_id>
  </id_info>
  <brief_title>A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkahest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkahest, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the safety, tolerability, and feasibility of GRF6019, a&#xD;
      plasma-derived product, administered as an intravenous (IV) infusion, to subjects with mild&#xD;
      to moderate Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, dose-comparison concurrent control study to assess the&#xD;
      safety, tolerability, and feasibility of GRF6019, a plasma-derived product, administered by&#xD;
      intravenous (IV) infusion to subjects with mild to moderate Alzheimer's disease.&#xD;
&#xD;
      Subjects will be randomized 1:1 to a low dose or a high dose of active treatment in a&#xD;
      double-blind manner. All subjects will receive one infusion per day at the randomized dose&#xD;
      for 5 consecutive days during Week 1 and, again, during Week 13 (for a total of 10 doses per&#xD;
      subject). All IV infusions will take place at an inpatient research unit while the follow-up&#xD;
      visits after each treatment period will be on an outpatient basis. Subjects will participate&#xD;
      for a total of 6 months in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Actual">May 24, 2019</completion_date>
  <primary_completion_date type="Actual">May 24, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Treatment-emergent Adverse Events (Safety)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Treatment-emergent adverse events identified by MedDRA preferred term and grouped by MedDRA System Organ Class</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Mini-Mental State Examination (MMSE)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Changes in scores on the MMSE. The MMSE consists of 5 components: orientation to time and place, registration of 3 words, attention and calculation, recall of 3 words, and language. The scores from the 5 components are summed to obtain the overall MMSE total score. The MMSE total score can range from 0 to 30, with higher scores indicating better cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASCog/11)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Changes in scores on the 11-item ADASCog/11. The ADAS-Cog/11 includes 11 items assessing cognitive function. The domains include memory, language, praxis, and orientation. There are 70 possible points. Higher scores reflect greater cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Clinical Dementia Rating Scale - Sum of Boxes (CDR-SOB)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Changes in the CDR-SOB. The CDR characterizes functioning in 6 domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. The score is obtained by summing each of the domain box scores. Scores range from 0 to 18 with higher scores reflecting worse cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Changes in the ADCS-ADL23. The ADCS-ADL23 assesses basic and instrumental activities of daily living covering physical and mental functioning and independence in self-care. The score ranges from 0 to 78 with higher scores indicating less functional impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The ADCS-CGIC focuses on clinicians' observations of change in the subject's cognitive, functional, and behavioral performance since the beginning of a trial. The ADCS-CGIC is a 7-point scale with lower values (&lt;4) representing an improvement, higher values (&gt;4) representing a worsening, and a value of 4 indicating no change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Neuropsychiatric Inventory Questionnaire (NPI-Q)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Change on the NPI-Q. The NPI-Q comprises 12 domains: delusions, hallucinations, dysphoria, apathy, euphoria, disinhibition, aggressivity and restlessness, irritability, anxiety aberrant motor behavior, appetite and eating disorders, and nocturnal behavior. The severity of the reported symptoms is assessed on a 3-point scale. The total severity score can range from 0 to 36 with higher scores representing worse severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Mild to Moderate Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>GRF6019 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a low dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GRF6019 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a high dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRF6019</intervention_name>
    <description>GRF6019 for IV infusion</description>
    <arm_group_label>GRF6019 High Dose</arm_group_label>
    <arm_group_label>GRF6019 Low Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of probable AD based upon the National Institute on Aging-Alzheimer's&#xD;
             Association (NIA-AA) Criteria&#xD;
&#xD;
          -  MMSE Score 12-24 inclusive&#xD;
&#xD;
          -  Modified Hachinski Ischemia Scale (MHIS) score of â‰¤ 4&#xD;
&#xD;
          -  Provided a signed and dated informed consent form (either the subject and/or subject's&#xD;
             legal representative as well as the trial partner)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of clinically relevant neurological disorder(s) other than probable AD&#xD;
&#xD;
          -  History of blood coagulation disorders or hypercoagulability; any concurrent use of an&#xD;
             anticoagulant therapy. (e.g., heparin, warfarin, thrombin inhibitors, Factor Xa&#xD;
             inhibitors). Use of antiplatelet drugs (e.g., aspirin or clopidogrel) is acceptable.&#xD;
&#xD;
          -  Initiation or change in the dosage of cholinesterase inhibitors (AChEI), memantine,&#xD;
             Axona, vitamin E supplementation or selegiline within 3 months prior to screening.&#xD;
&#xD;
          -  Heart disease (or history thereof), as evidenced by myocardial infarction, unstable,&#xD;
             new onset or severe angina, or congestive heart failure (New York Association Class&#xD;
             II, III or IV) in the 6 months prior to dosing; uncontrolled high blood pressure&#xD;
             (systolic blood pressure of 160 mmHg or higher and/or diastolic blood&#xD;
&#xD;
          -  Prior hypersensitivity reaction to any human blood product or intravenous infusion;&#xD;
             any known clinically significant drug allergy.&#xD;
&#xD;
          -  Treatment with any human blood product, including transfusions and intravenous&#xD;
             immunoglobulin, during the 6 months prior to screening.&#xD;
&#xD;
          -  History of immunoglobulin A (IgA), haptoglobulin or C1 inhibitor deficiency; stroke,&#xD;
             anaphylaxis, or thromboembolic complications of intravenous immunoglobulins.&#xD;
&#xD;
          -  Hemoglobin &lt;10 g/dL in women; and &lt;11 g/dL in men.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alkahest Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Alkahest, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synergy East</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNS Network</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Jewish Health Systems</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Clinical Research</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Medical Institute</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Serenity Inpatient</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <results_first_submitted>October 5, 2020</results_first_submitted>
  <results_first_submitted_qc>October 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2020</results_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03520998/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03520998/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GRF6019 Low Dose</title>
          <description>Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
        </group>
        <group group_id="P2">
          <title>GRF6019 High Dose</title>
          <description>High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GRF6019 Low Dose</title>
          <description>Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
        </group>
        <group group_id="B2">
          <title>GRF6019 High Dose</title>
          <description>High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.9" spread="6.26"/>
                    <measurement group_id="B2" value="72.7" spread="7.21"/>
                    <measurement group_id="B3" value="74.3" spread="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Treatment-emergent Adverse Events (Safety)</title>
        <description>Treatment-emergent adverse events identified by MedDRA preferred term and grouped by MedDRA System Organ Class</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>GRF6019 Low Dose</title>
            <description>Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
          <group group_id="O2">
            <title>GRF6019 High Dose</title>
            <description>High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Treatment-emergent Adverse Events (Safety)</title>
          <description>Treatment-emergent adverse events identified by MedDRA preferred term and grouped by MedDRA System Organ Class</description>
          <population>Safety Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mini-Mental State Examination (MMSE)</title>
        <description>Changes in scores on the MMSE. The MMSE consists of 5 components: orientation to time and place, registration of 3 words, attention and calculation, recall of 3 words, and language. The scores from the 5 components are summed to obtain the overall MMSE total score. The MMSE total score can range from 0 to 30, with higher scores indicating better cognition.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Evaluable Set and Per Protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>GRF6019 Low Dose</title>
            <description>Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
          <group group_id="O2">
            <title>GRF6019 High Dose</title>
            <description>High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
        </group_list>
        <measure>
          <title>The Mini-Mental State Examination (MMSE)</title>
          <description>Changes in scores on the MMSE. The MMSE consists of 5 components: orientation to time and place, registration of 3 words, attention and calculation, recall of 3 words, and language. The scores from the 5 components are summed to obtain the overall MMSE total score. The MMSE total score can range from 0 to 30, with higher scores indicating better cognition.</description>
          <population>Evaluable Set and Per Protocol Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="4.3"/>
                    <measurement group_id="O2" value="1.5" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASCog/11)</title>
        <description>Changes in scores on the 11-item ADASCog/11. The ADAS-Cog/11 includes 11 items assessing cognitive function. The domains include memory, language, praxis, and orientation. There are 70 possible points. Higher scores reflect greater cognitive impairment.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Evaluable Set and Per Protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>GRF6019 Low Dose</title>
            <description>Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
          <group group_id="O2">
            <title>GRF6019 High Dose</title>
            <description>High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
        </group_list>
        <measure>
          <title>Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASCog/11)</title>
          <description>Changes in scores on the 11-item ADASCog/11. The ADAS-Cog/11 includes 11 items assessing cognitive function. The domains include memory, language, praxis, and orientation. There are 70 possible points. Higher scores reflect greater cognitive impairment.</description>
          <population>Evaluable Set and Per Protocol Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="5.1"/>
                    <measurement group_id="O2" value="-0.9" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Clinical Dementia Rating Scale - Sum of Boxes (CDR-SOB)</title>
        <description>Changes in the CDR-SOB. The CDR characterizes functioning in 6 domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. The score is obtained by summing each of the domain box scores. Scores range from 0 to 18 with higher scores reflecting worse cognition.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Evaluable Set and Per Protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>GRF6019 Low Dose</title>
            <description>Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
          <group group_id="O2">
            <title>GRF6019 High Dose</title>
            <description>High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
        </group_list>
        <measure>
          <title>The Clinical Dementia Rating Scale - Sum of Boxes (CDR-SOB)</title>
          <description>Changes in the CDR-SOB. The CDR characterizes functioning in 6 domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. The score is obtained by summing each of the domain box scores. Scores range from 0 to 18 with higher scores reflecting worse cognition.</description>
          <population>Evaluable Set and Per Protocol Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="2.3"/>
                    <measurement group_id="O2" value="0.21" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)</title>
        <description>Changes in the ADCS-ADL23. The ADCS-ADL23 assesses basic and instrumental activities of daily living covering physical and mental functioning and independence in self-care. The score ranges from 0 to 78 with higher scores indicating less functional impairment.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Evaluable Set and Per Protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>GRF6019 Low Dose</title>
            <description>Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
          <group group_id="O2">
            <title>GRF6019 High Dose</title>
            <description>High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
        </group_list>
        <measure>
          <title>The Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)</title>
          <description>Changes in the ADCS-ADL23. The ADCS-ADL23 assesses basic and instrumental activities of daily living covering physical and mental functioning and independence in self-care. The score ranges from 0 to 78 with higher scores indicating less functional impairment.</description>
          <population>Evaluable Set and Per Protocol Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="7.4"/>
                    <measurement group_id="O2" value="-1.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)</title>
        <description>The ADCS-CGIC focuses on clinicians' observations of change in the subject's cognitive, functional, and behavioral performance since the beginning of a trial. The ADCS-CGIC is a 7-point scale with lower values (&lt;4) representing an improvement, higher values (&gt;4) representing a worsening, and a value of 4 indicating no change.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Evaluable Set and Per Protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>GRF6019 Low Dose</title>
            <description>Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
          <group group_id="O2">
            <title>GRF6019 High Dose</title>
            <description>High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
        </group_list>
        <measure>
          <title>The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)</title>
          <description>The ADCS-CGIC focuses on clinicians' observations of change in the subject's cognitive, functional, and behavioral performance since the beginning of a trial. The ADCS-CGIC is a 7-point scale with lower values (&lt;4) representing an improvement, higher values (&gt;4) representing a worsening, and a value of 4 indicating no change.</description>
          <population>Evaluable Set and Per Protocol Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.8"/>
                    <measurement group_id="O2" value="4.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Neuropsychiatric Inventory Questionnaire (NPI-Q)</title>
        <description>Change on the NPI-Q. The NPI-Q comprises 12 domains: delusions, hallucinations, dysphoria, apathy, euphoria, disinhibition, aggressivity and restlessness, irritability, anxiety aberrant motor behavior, appetite and eating disorders, and nocturnal behavior. The severity of the reported symptoms is assessed on a 3-point scale. The total severity score can range from 0 to 36 with higher scores representing worse severity.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Evaluable Set and Per Protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>GRF6019 Low Dose</title>
            <description>Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
          <group group_id="O2">
            <title>GRF6019 High Dose</title>
            <description>High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
          </group>
        </group_list>
        <measure>
          <title>The Neuropsychiatric Inventory Questionnaire (NPI-Q)</title>
          <description>Change on the NPI-Q. The NPI-Q comprises 12 domains: delusions, hallucinations, dysphoria, apathy, euphoria, disinhibition, aggressivity and restlessness, irritability, anxiety aberrant motor behavior, appetite and eating disorders, and nocturnal behavior. The severity of the reported symptoms is assessed on a 3-point scale. The total severity score can range from 0 to 36 with higher scores representing worse severity.</description>
          <population>Evaluable Set and Per Protocol Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="3.8"/>
                    <measurement group_id="O2" value="-1.2" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GRF6019 Low Dose</title>
          <description>Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
        </group>
        <group group_id="E2">
          <title>GRF6019 High Dose</title>
          <description>High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Infusion site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Communications</name_or_title>
      <organization>Alkahest, Inc.</organization>
      <phone>(650) 801-0474</phone>
      <email>info@alkahest.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

